ClinicalTrials.gg
CompletedNCT01048333Updated Oct 25, 2012Results posted

Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

A Phase 2 interventional study of Formoterol and Salmeterol in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 17 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
46th of 89
109 · median 120
Started
2010
with 2 others
Phase 2
12 of 89
none open now
Registered
29th of 89
by date
Lead sponsor
20 of 89
AstraZeneca

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 46th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 2, and was the 29th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

  • Primary objective is to evaluate time to onset of effect of formoterol, 9 μg single dose,compared with salmeterol, 50 μg single dose, in patients with moderate COPD.Forced Expiratory Volume in 1 second (FEV1) measured by spirometry 5 minutes postdose.
  • Secondary efficacy variables: Average FEV1 during the first 15 minutes (area under the FEV1 curve from 0 to 15 minutes), Average FEV1 during 120 minutes (area under the FEV1 curve from 0 to 120 minutes)
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Onset of effect
  • COPD
  • Oxis Turbuhaler
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of according to GOLD guidelines, and current COPD symptoms
  • A current or previous smoking history equivalent to 10 or more packs per year (1 pack year = 20 cigarettes smoked per day for one year).
  • Documented use of a short-acting inhaled bronchodilator (β2-agonist or anticholinergics) as reliever medication.

Exclusion criteria

Exclusion Criteria:

  • A history and/or current diagnosis of asthma.
  • Patients who have experienced exacerbation requiring hospitalisation and/or a course of antibiotics and/or a course of systemic within 30 days (from end of exacerbation treatment) prior to Visit 1 and/or during the run-in period.
  • A history and/or current diagnosis of atopic diseases such as allergic rhinitis or eczema before the age of 40.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Formoterol, then Salmeterol, then Placebo

    Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler

    Drug: Formoterol · Drug: Salmeterol · Drug: Placebo

  • Experimental
    Salmeterol, then Palcebo, then Formoterol

    Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus

    Drug: Formoterol · Drug: Salmeterol · Drug: Placebo

  • Experimental
    Placebo, then Formoterol, then Salmeterol

    Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler

    Drug: Formoterol · Drug: Salmeterol · Drug: Placebo

  • Experimental
    Formoterol, then Placebo, then Salmeterol

    Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler

    Drug: Formoterol · Drug: Salmeterol · Drug: Placebo

  • Experimental
    Salmeterol, then Formoterol, then Placebo

    Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler

    Drug: Formoterol · Drug: Salmeterol · Drug: Placebo

  • Experimental
    Placebo, then Salmeterol, then Formoterol

    Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus

    Drug: Formoterol · Drug: Salmeterol · Drug: Placebo

Interventions

  • Formoterol Turbuhaler 9 μg and Placebo Diskus

  • Salmeterol Diskus 50 μg and Placebo Turbuhaler

  • DrugPlacebo

    Placebo Diskus and Placebo Turbuhaler

06

What researchers measure

Primary outcomes

  1. FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose

    FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1

    Time frame: Pre-dose and 5 minutes post-dose

Secondary outcomes

  1. Average FEV1 During the First 15 Minutes Post Dose

    Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1

    Time frame: Pre dose and 15 minutes post dose

  2. Average FEV1 During 120 Minutes Post Dose

    Average FEV1 during 120 minutes post dose, change versus pre dose FEV1

    Time frame: Pre dose and 120 minutes post dose

  3. Percentage of Patients Who Has Achieved at Least 12 % Increase in FEV1

    Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1

    Time frame: Pre dose, 5, 10, 15, 20, 30, 40, 50, 60 and 120 minutes post dose

  4. Adverse Events

    Number of participants with at least 1 AE.

    Time frame: At baseline and at each day of treatment

07

Results

Posted Oct 25, 2012

Participant flow

Patients recruited at 14 clinics in 3 countries: Sweden (4 clinics); Italy (6 clinics); Spain (6 clinics)between January and May 2010

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFormoterol, Then Salmeterol, Then PlaceboSalmeterol, Then Palcebo, Then FormoterolPlacebo, Then Formoterol, Then SalmeterolFormoterol, Then Placebo, Then SalmeterolSalmeterol, Then Formoterol, Then PlaceboPlacebo, Then Salmeterol, Then Formoterol
Started211916181718
Completed211916181718
Not completed000000
Wash-Out Period 1 of 2 - 7 Days
Participant flow — Wash-Out Period 1 of 2 - 7 Days
MilestoneFormoterol, Then Salmeterol, Then PlaceboSalmeterol, Then Palcebo, Then FormoterolPlacebo, Then Formoterol, Then SalmeterolFormoterol, Then Placebo, Then SalmeterolSalmeterol, Then Formoterol, Then PlaceboPlacebo, Then Salmeterol, Then Formoterol
Started211916181718
Completed211916181718
Not completed000000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFormoterol, Then Salmeterol, Then PlaceboSalmeterol, Then Palcebo, Then FormoterolPlacebo, Then Formoterol, Then SalmeterolFormoterol, Then Placebo, Then SalmeterolSalmeterol, Then Formoterol, Then PlaceboPlacebo, Then Salmeterol, Then Formoterol
Started211916181718
Completed211916181718
Not completed000000
Wash-Out Period 2 of 2 - 7 Days
Participant flow — Wash-Out Period 2 of 2 - 7 Days
MilestoneFormoterol, Then Salmeterol, Then PlaceboSalmeterol, Then Palcebo, Then FormoterolPlacebo, Then Formoterol, Then SalmeterolFormoterol, Then Placebo, Then SalmeterolSalmeterol, Then Formoterol, Then PlaceboPlacebo, Then Salmeterol, Then Formoterol
Started211916181718
Completed211816181718
Not completed010000
Withdrew: Adverse event010000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneFormoterol, Then Salmeterol, Then PlaceboSalmeterol, Then Palcebo, Then FormoterolPlacebo, Then Formoterol, Then SalmeterolFormoterol, Then Placebo, Then SalmeterolSalmeterol, Then Formoterol, Then PlaceboPlacebo, Then Salmeterol, Then Formoterol
Started211816181718
Completed211816181718
Not completed000000

Outcome measures

PrimaryFEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose

FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1

Time frame:
Pre-dose and 5 minutes post-dose
Reported as:
Geometric mean · percentage change
FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose
percentage changeFormoterolSalmeterolPlacebo
FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose1.072 (1.055 to 1.088)1.041 (1.025 to 1.057)1.007 (0.992 to 1.023)
SecondaryAverage FEV1 During the First 15 Minutes Post Dose

Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1

Time frame:
Pre dose and 15 minutes post dose
Reported as:
Geometric mean · percentage change
Average FEV1 During the First 15 Minutes Post Dose
percentage changeFormoterolSalmeterolPlacebo
Average FEV1 During the First 15 Minutes Post Dose1.064 (1.052 to 1.077)1.041 (1.030 to 1.053)1.012 (1.001 to 1.024)
SecondaryAverage FEV1 During 120 Minutes Post Dose

Average FEV1 during 120 minutes post dose, change versus pre dose FEV1

Time frame:
Pre dose and 120 minutes post dose
Reported as:
Geometric mean · percentage change
Average FEV1 During 120 Minutes Post Dose
percentage changeFormoterolSalmeterolPlacebo
Average FEV1 During 120 Minutes Post Dose1.096 (1.079 to 1.112)1.082 (1.066 to 1.098)1.014 (0.999 to 1.029)
SecondaryPercentage of Patients Who Has Achieved at Least 12 % Increase in FEV1

Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1

Time frame:
Pre dose, 5, 10, 15, 20, 30, 40, 50, 60 and 120 minutes post dose
Reported as:
Number · Percentage of Participants
Percentage of Patients Who Has Achieved at Least 12 % Increase in FEV1
Percentage of ParticipantsFormoterolSalmeterolPlacebo
5 min23.19.26.4
10 min38.017.67.3
15 min39.823.99.2
20 min44.427.510.1
30 min45.432.113.8
40 min49.136.715.6
50 min53.740.416.5
60 min54.643.118.3
120 min55.648.620.2
Statistical analysis
  • Formoterol vs Salmeterol · Regression, Cox · p = 0.002 · Hazard ratio (hr): 2.090 · 95% CI 1.31 to 3.35
  • Formoterol vs Placebo · Regression, Cox · p = 0.001 · Hazard ratio (hr): 6.534 · 95% CI 3.55 to 12.02
  • Salmeterol vs Placebo · Regression, Cox · p = 0.001 · Hazard ratio (hr): 3.127 · 95% CI 1.77 to 5.52
SecondaryAdverse Events

Number of participants with at least 1 AE.

Time frame:
At baseline and at each day of treatment
Reported as:
Number · Participants
Adverse Events
ParticipantsFormoterolSalmeterolPlacebo
Adverse Events662

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Formoterol—0/108 (0%)0/108 (0%)
Salmeterol—0/109 (0%)0/109 (0%)
Placebo—0/109 (0%)0/109 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean66.5 (41.0 to 84.0)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female28
Male81
08

Study locations

17 sites
  • Research Site
    Bussolengo, Italy
  • Research Site
    Cassano Delle Murge, Italy
  • Research Site
    Catanzaro, Italy
  • Research Site
    Cava dei Tirreni, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Palermo, Italy
  • Research Site
    Parma, Italy
  • Research Site
    Pisa, Italy
  • Research Site
    Prato, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Barcelona, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Goteborg, Sweden
  • Research Site
    Linkoping, Sweden
  • Research Site
    Lulea, Sweden
  • Research Site
    Lund, Sweden
09

References and documents

Publications

  • Cazzola M, Paggiaro P, Palange P, Bjermer L, Ausin P, Carlsson LG, Ekelund J, Lotvall J. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study. Clin Drug Investig. 2012 Mar 1;32(3):147-55. doi: 10.2165/11630880-000000000-00000. PubMed 22235841 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2010
First posted
Jan 13, 2010
Start
Jan 2010
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Oct 25, 2012
Last update
Oct 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01048333
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 13, 2010
Start date
Jan 2010
Primary completion
May 2010
Completion
May 2010
Results posted
Oct 25, 2012
Last update
Oct 25, 2012

Study contacts

Mario Cazzola, professor
principal investigator · Italy
Georgios Stratelis
study director · AstraZeneca MC Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion